Novartis Gene Therapies - Strategic SWOT Analysis Review

Novartis Gene Therapies - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the companys key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy summarization of the companys business strategy.
- SWOT analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list of key locations and subsidiaries of the company, including contact details.

Highlights

Novartis Gene Therapies, formerly AveXis Inc, is a biotechnology company. It operates as a subsidiary of Novartis AG. The company develops treatments for rare and potentially fatal neurological genetic diseases. The companys product, Zolgensm, a proprietary gene therapy candidate for pediatric patients for the treatment of spinal muscular atrophy. It is also pursuing gene therapies for Rett syndrome (AVXS-201) and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene (AVXS-301). It works in collaboration with various academic institutes and research centers to advance its investigational product candidates. Novartis Gene Therapies is headquartered in Bannockburn, Illinois, the US.

Novartis Gene Therapies Key Recent Developments

Aug 06,2020: Catalent gene therapy facility receives FDA approval as an additional manufacturing site for AveXis gene therapy
Aug 14,2019: FDA Issues Form 483 to Avexis API Manufacturing Facility in San Diego, CA, US
Aug 14,2019: AveXis Statement on Changes to Senior Leadership Team
Apr 01,2019: AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
Feb 18,2019: Gene Therapy Firm AveXis to Expand in Durham County Adding 200 Jobs and $60 Million in Investment

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this reports analysis of the companys business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors business structure and strategies with detailed SWOT analysis. In this, the companys core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this reports detailed insight into the companys strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.



Section 1 - About the Company
Novartis Gene Therapies - Key Facts
Novartis Gene Therapies - Key Employees
Novartis Gene Therapies - Major Products and Services
Novartis Gene Therapies - History
Novartis Gene Therapies - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 Company Analysis
Company Overview
Novartis Gene Therapies - Business Description
Novartis Gene Therapies - SWOT Analysis
SWOT Analysis - Overview
Novartis Gene Therapies - Strengths
Novartis Gene Therapies - Weaknesses
Novartis Gene Therapies - Opportunities
Novartis Gene Therapies - Threats
Novartis Gene Therapies - Key Competitors
Section 3 Companys Lifesciences Financial Deals and Alliances
Novartis Gene Therapies, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Novartis Gene Therapies, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Novartis Gene Therapies, Recent Deals Summary
Section 4 Companys Recent Developments
Aug 06, 2020: Catalent gene therapy facility receives FDA approval as an additional manufacturing site for AveXis gene therapy
Aug 14, 2019: AveXis Statement on Changes to Senior Leadership Team
Aug 14, 2019: FDA Issues Form 483 to Avexis API Manufacturing Facility in San Diego, CA, US
Apr 01, 2019: AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
Feb 18, 2019: Gene Therapy Firm AveXis to Expand in Durham County Adding 200 Jobs and $60 Million in Investment
Section 5 Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables


Novartis Gene Therapies, Key Facts
Novartis Gene Therapies, Key Employees
Novartis Gene Therapies, Major Products and Services
Novartis Gene Therapies, History
Novartis Gene Therapies, Subsidiaries
Novartis Gene Therapies, Key Competitors
Novartis Gene Therapies, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Novartis Gene Therapies, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Novartis Gene Therapies, Recent Deals Summary

List Of Figures


Novartis Gene Therapies, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Novartis Gene Therapies, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

Novartis Gene Therapies - Strategic SWOT Analysis Review

Novartis Gene Therapies - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information

USD 125 View Report

Novartis India Limited Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Novartis India Limited Company Profile is a detailed strategic and analytical report on Novartis India Limited. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Global Emerging Gene Therapies Market Research Report 2019-2023

Emerging Gene Therapies Trends within the Technological, Clinical, Regulatory and Competitive Landscape Genomic surgery is increasingly a reality. In the context of China-US trade war and global economic volatility

USD 2850 View Report

Genetic Modification Therapies Clinical Applications: Gene Therapies, Genetically Modified Cell Therapies, RNA Therapies and Gene Editing

Report ScopeThe study scope includes clinical therapies using gene editing, gene therapy, genetically modified cell therapy (chimeric antigen receptor T-cells, or CAR T-cells) or RNA therapy platforms. Delivery technologies covered

USD 2750 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available